Commission Implementing Decision (EU) 2016/1190
of 19 July 2016
authorising the placing on the market of trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
(notified under document C(2016) 4567)
(Only the English text is authentic)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Whereas:
On 8 November 2012, the company DSM Nutritional Products Ltd made a request to the competent authorities of Ireland to place trans-resveratrol on the market as a novel food ingredient within the meaning of point (f) of Article 1(2) of Regulation (EC) No 258/97.
On 28 June 2013, the competent food assessment body of Ireland issued its initial assessment report. In that report it came to the conclusion that trans-resveratrol meets the criteria for novel food ingredients set out in Article 3(1) of Regulation (EC) No 258/97.
On 4 September 2013, the Commission forwarded the initial assessment report to the other Member States.
Reasoned objections were raised within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.
On 3 April 2014, the Commission consulted the European Food Safety Authority (EFSA) asking it to carry out an additional assessment for trans-resveratrol as novel food ingredient in accordance with Regulation (EC) No 258/97.
That opinion gives sufficient grounds to establish that trans-resveratrol as a novel food ingredient complies with the criteria laid down in Article 3(1) of Regulation (EC) No 258/97.
In its opinion, EFSA also indicated that trans-resveratrol may interact with specific medicines therefore, it is necessary to inform the consumers when consumed in combination with medicines.
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
HAS ADOPTED THIS DECISION:
Article 1
Trans-resveratrol as specified in the Annex to this Decision may be placed on the market in the Union as a novel food ingredient to be used in food supplements in capsule or tablet form intended for adult population only with a maximum dose of 150 mg per day without prejudice to the provisions of Directive 2002/46/EC.
Article 2
1.
The designation of trans-resveratrol authorised by this Decision on the labelling of the foodstuffs containing it shall be ‘trans-resveratrol’.
2.
The labelling of food supplements containing trans-resveratrol shall bear a statement that people using medicines should only consume the product under medical supervision.
Article 3
This Decision is addressed to DSM Nutritional Products Ltd, Heanor Gate Ind. Est. Heanor, Derbyshire, United Kingdom.
Done at Brussels, 19 July 2016.
For the Commission
Vytenis Andriukaitis
Member of the Commission
ANNEXSPECIFICATION OF TRANS-RESVERATROL
Definition:
Chemical name | 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol |
|---|---|
Chemical formula | C14H12O3 |
Molecular weight | 228,25 Da |
CAS No | 501-36-0 |
Description: Trans-resveratrol is off-white to beige crystals.
Purity:
Trans-resveratrol | Not less than 99 % |
Total by-products (related substances) | Not more than 0,5 % |
Any single related substance | Not more than 0,1 % |
Lead | Not more than 1 ppm |
Mercury | Not more than 0,1 ppm |
Cadmium | Not more than 0,5 ppm |
Arsenic | Not more than 1 ppm |
Loss on drying | Not more than 0,5 % |
Sulphated ash | Not more than 0,1 % |
Diisopropylamine | Not more than 50 mg/kg |